Review addresses treating obesity in heart failure patients where the obesity paradox applies, evaluating how GLP-1 drugs can provide metabolic benefits without worsening cardiac outcomes.
Key findingReview addresses treating obesity in heart failure patients where the obesity paradox applies, evalu
What the researchers found
Review addresses treating obesity in heart failure patients where the obesity paradox applies, evaluating how GLP-1 drugs can provide metabolic benefits without worsening cardiac outcomes.
Why it matters
These findings are relevant to the growing population of patients using or considering peptide-based therapies.
The numbers in context
Review examines observational data on BMI and survival in heart failure, plus emerging evidence on GLP-1 drugs in this population.
How the study worked
Study design and methodology detailed in the full publication.
Who was studied
Heart failure patients with obesity across reviewed studies
What this study cannot tell us
Study limitations discussed in the full publication.
How to read the evidence
Evidence assessment based on study design in publication.
When this study was published
Published in 2025.
The bigger picture
This study contributes to the expanding evidence for peptide-based therapeutics in clinical medicine.
Questions still open
- What are the long-term implications?
- How do results compare to existing evidence?
- What further research is needed?
Common questions
What does this study mean for patients?
How reliable are these findings?
Read the original research
The Treatment of Obesity in the Context of the Obesity Paradox in Patients with Heart Failure: A Narrative Review.
Current cardiology reports, 28(1), 4
Citation
Alebna, Pamela L; Martey, Sarah; Mehta, Anurag; Lavie, Carl J; Carbone, Salvatore. (2025). The Treatment of Obesity in the Context of the Obesity Paradox in Patients with Heart Failure: A Narrative Review.. Current cardiology reports, 28(1), 4. https://doi.org/10.1007/s11886-025-02333-5